UnknownNot Applicable

The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC

China60 participantsStarted 2016-10-31

Plain-language summary

To determine changes in retinal and choroidal capillaries with optical coherence tomographic angiography (OCTA) after half-dose photodynamic therapy (hd-PDT) in eyes with central serous chorioretinopathy (CSC).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. CSC diagnosed by FFA and ICGA, where the active leakage was just located in macular fovea with SRF confirmed by OCT
✓. Patient age ≥18 years
✓. BCVA ≥35 letters on ETDRS charts
✓. Persistent CSC for a period of time or patients were anxiety about the symptom and asking for treatment
✓. Lack of either spontaneous improvement or improvement induced by empirical treatment such as pharmaceutical drug
✓. The provision of written informed consent -

Exclusion criteria

✕. The presence of any other chorioretinal diseases that may affect the studies, such as age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV)
✕. Patients who had received any previous treatment, including PDT, intraocular drug injection or focal thermal laser photocoagulation for CSC
✕. Patients with PED in macular fovea which the average diameter (transverse diameter and vertical diameter) was more than 300 microns
✕. Patients with high myopia, defined as a refractive error (spherical equivalent) \< -6.00 diopters, or an axial length \>26.5 mm
✕. Patients with media opacities, or signal strength index of the images \< 60
✕. Patients under corticosteroid therapy -

What they're measuring

Changes of retinal capillaries after hd-PDT

Timeframe: 1 month, 3 month

Trial details

NCT IDNCT03692169

SponsorJin Chen-jin

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-10-10

Contact for this trial

Fabao Xu

15521250400 517311823@qq.com

View on ClinicalTrials.gov More Central Serous Chorioretinopathy trials